Strategic Partnerships for Fc-Engager Development

LoopLab Bio is advancing a first-in-class Fc-Engager platform, designed to promote durable, antigen-specific immune tolerance without broad immunosuppression.

We are actively seeking strategic partnerships with pharma and biotech companies to accelerate the development of this technology through:

• Co-development of lead assets from discovery to clinical stage

• Licensing opportunities for indication-specific applications

• Strategic alliances to combine Fc-Engager technology with partner pipelines (enzymes, antibodies, or cell/gene therapies)

Partnership areas of focus:

• Autoimmune & allergy: Celiac disease, bullous pemphigoid, house dust mite allergy

• Rare metabolic disorders / ADA prevention: Pompe, Fabry, Pegloticase (ERT adjuncts)

• Transplant tolerance: Imlifidase-FcE concepts to manage antibody rebound and redosing

• Emerging areas: potential enabling of gene therapy through tolerance induction

Our robust IP position, validated preclinical systems, and experienced leadership team provide a strong foundation for collaboration. We look forward to building long-term, balanced partnerships that bring durable immune tolerance therapies to patients worldwide.